Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma
Abstract Background Multiple myeloma (MM) remains incurable despite recent therapeutic advances. RAS mutations are frequently associated with relapsed/refractory disease. Efforts to target the mitogen-activated protein kinase (MAPK) pathway with the MEK inhibitor, trametinib (Tra) have been limited...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2020-03-01
|
| coleção: | BMC Cancer |
| Assuntos: | |
| Acesso em linha: | http://link.springer.com/article/10.1186/s12885-020-06735-2 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|